Samaritan Pharmaceuticals (OTCBB:SPHC) (http://www.samaritanpharma.com), a biopharmaceutical company committed to commercializing new innovative therapeutic drugs, announced that it has filed an IND (Investigational New Drug) application for SP-6310 in the treatment of HIV-infected patients with abnormal cortisol levels.

Samaritan Pharmaceuticals (OTCBB:SPHC) (http://www.samaritanpharma.com), a biopharmaceutical company committed to commercializing new and innovative therapeutic drugs, announced today that it has received pricing approval for Rapydan(R) from the Greek Ministry of Development and is launching the novel rapid-onset anesthetic patch in Greece this week.

Samaritan Pharmaceuticals (OTCBB:SPHC) (http://www.samaritanpharma.com), a biopharmaceutical company, committed to commercializing new innovative therapeutic drugs, announces its proprietary HIV drug, SP-01A, is awarded US patent No: US 7,354,906 B2, entitled "Composition of Anti-HIV drugs and Anti-Cortisol compounds and Methods for Decreasing the Side Effects of Anti-HIV drugs in Humans" by the Director of the United States Patent and Trademark Office.

Samaritan Pharmaceuticals (OTCBB:SPHC) (http://www.samaritanpharma.com), a biopharmaceutical company committed to commercializing new innovative therapeutic drugs, has received notification that the claims in the patent application for "Neuroprotective Spirostenol Pharmaceutical Compositions" covering Caprospinol (SP-233) have been allowed by the Australian Patent Office.

Samaritan Pharmaceuticals has acquired the rights from Abiogen Pharma of Italy to distribute and sell the specialty pharmaceutical, Abioklad in Greece, Cyprus, and Turkey.